Janux Therapeutics Inc (NASDAQ: JANX) is -40.14% lower on its value in year-to-date trading and has touched a low of $22.52 and a high of $71.71 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The JANX stock was last observed hovering at around $33.20 in the last trading session, with the day’s loss setting it -1.15%.
Currently trading at $32.05, the stock is 9.78% and 5.69% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.05 million and changing -3.46% at the moment leaves the stock -25.96% off its SMA200. JANX registered -42.85% loss for a year compared to 6-month loss of -41.04%. The firm has a 50-day simple moving average (SMA 50) of $30.3244 and a 200-day simple moving average (SMA200) of $43.290226.
The stock witnessed a 19.54% gain in the last 1 month and extending the period to 3 months gives it a -28.44%, and is -0.06% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.91% over the week and 7.13% over the month.
Janux Therapeutics Inc (JANX) has around 81 employees, a market worth around $1.89B and $10.59M in sales. Profit margin for the company is -651.62%. Distance from 52-week low is 42.32% and -55.31% from its 52-week high. The company has generated returns on investments over the last 12 months (-6.61%).
with sales reaching $650k over the same period.The EPS is expected to shrink by -41.41% this year, but quarterly earnings will post -75.10% year-over-year. Quarterly sales are estimated to shrink -48.08% in year-over-year returns.
300.0 institutions hold shares in Janux Therapeutics Inc (JANX), with institutional investors hold 121.91% of the company’s shares. The shares outstanding are 59.06M, and float is at 49.40M with Short Float at 18.91%. Institutions hold 113.33% of the Float.
The top institutional shareholder in the company is RA CAPITAL MANAGEMENT, L.P. with over 9.17 million shares valued at $383.95 million. The investor’s holdings represent 16.8326 of the JANX Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 7.78 million shares valued at $325.8 million to account for 14.2835 of the shares outstanding. The other top investors are ORBIMED ADVISORS LLC which holds 2.98 million shares representing 5.4724 and valued at over $124.82 million, while BLACKROCK INC. holds 4.3047 of the shares totaling 2.34 million with a market value of $98.19 million.
Janux Therapeutics Inc (JANX) Insider Activity
Janux Therapeutics Inc disclosed in a document filed with the SEC on Apr 21 ’25 that Meyer Andrew Hollman (Chief Business Officer) sold a total of 3,334 shares of the company’s common stock. The trade occurred on Apr 21 ’25 and was made at $30.00 per share for $0.1 million. Following the transaction, the insider now directly holds 82139.0 shares of the JANX stock.
Still, SEC filings show that on Apr 21 ’25, ANDREW MEYER (Officer) Proposed Sale 3,334 shares at an average price of $29.69 for $98986.0. The insider now directly holds shares of Janux Therapeutics Inc (JANX).
